Health
Eisai Shares Sink on Surprise EU Rejection of Alzheimer’s Drug
- ‘A very big negative surprise,’ Jefferies analysts write
- Eli Lilly’s Alzheimer’s treatment won FDA approval in July
This article is for subscribers only.
Eisai shares sink more than 12%, the most in three years, after European drug regulators rejected an Alzheimer’s therapy jointly developed with Biogen Inc., in what could be a blow to their global sales expansion plan.
The European Medicines Agency’s Committee for Medicinal Products for Human Use, or CHMP, recommended refusing granting of marketing authorization for Leqembi, citing safety concerns including side effects that involve swelling and potential bleeding in the brain.